HER2-CAR T-cell therapy induces antitumor activity in high-risk sarcomas in phase I trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers at Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital, and Houston Methodist published results of a phase I clinical trial of a novel immunotherapy for high-risk sarcomas on April 24 in Nature Cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login